Q-omics provides the consensus-scored BRCC3P1 profile across patient tissues and cancer cell-line models. BRCC3P1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, BRCC3P1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, BRCC3P1 RNA expression shows 18,985 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where BRCC3P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRCC3P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRCC3P1 survival associations across molecular data types. BRCC3P1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRCC3P1 RNA expression–survival associations across cancer types. High BRCC3P1 expression shows unfavorable associations in MESO, KIRC and KICH, but favorable associations in ACC, LUAD and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for BRCC3P1 RNA expression.
This table summarizes BRCC3P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BRCC3P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRCC3P1 shows lower tumor expression in KIRC and higher tumor expression in COAD, STAD, BRCA, LUAD and LIHC. The KIRC box plot shows higher BRCC3P1 RNA expression in normal versus tumor tissue (log2 FC = −0.174, t-test p < 0.001).
This table shows molecular features associated with BRCC3P1 in patient tissues and cancer cell lines. In patient samples, BRCC3P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
